Cellectar Biosciences, Inc. Q2 2025 Earnings Recap

CLRB Q2 2025 August 14, 2025

Get alerts when CLRB reports next quarter

Cellectar Biosciences reported a strong second quarter, showcasing strategic advances in its clinical pipeline and regulatory strategies while securing additional funding to support future initiatives.

Earnings Per Share Beat

$-3.39 vs $-3.60 est.

+5.8% surprise

Market Reaction

1-Day -1.81%

5-Day +1.58%

30-Day +16.06%

See CLRB alongside your other holdings

Add to your portfolio — free

Key Takeaways

Submitted a new drug application for iopofosine I-131 for Waldenstrom's Macroglobulinemia under an accelerated approval pathway, emphasizing commitment to expedite treatment for rare diseases.
Secured €5.8 million in financing, boosting cash reserves to $11 million, sufficient to fund operations through Q2 2026.
Advanced discussions with potential partners to secure non-dilutive capital and expertise for iopofosine's global commercialization.
Research and development expenses significantly decreased to $2.4 million due to completed patient enrollment in the CLOVER-WaM study.
Timeline established for initiating a Phase I trial of CLR 125 in late 2025 or early 2026, expanding the company's radiopharmaceutical offerings.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CLRB on AllInvestView.

Next Q3 2025